| |
Good day, 360! | Here are some BIG movers today. Have a great trading day out there. Be the best prepared trader on the Street! | | FOCUS LISTπ | WALD - Up over 20% in the pre-market after reporting a 26% net revenue surge in Q2 | NRSN - Up over 14% in pre after reports it's in advanced talks with several multi-billion-dollar pharma companies to partner its lead drug | BOX - Up over 8% in pre after reporting positive Q2 financial results | | *sponsored by StocksToTrade | After 4 years of secrecy, one historic discovery is provoking veteran trader, Tim Bohen and his team of 11 developers, to go "beyond AI" and officially unveil the unique stock-scoring-system responsible for pinpointing dozens of 100%+ gains in both bear AND bull markets… | Don't Miss This World Premiere | |
|
| | HOTLISTπ₯ | WALD - Up over 20% in the pre-market after reporting a 26% net revenue surge in Q2 | Waldencast plc (WALD) operates in the beauty and wellness industry. It engages in developing, acquiring, accelerating, and scaling various brands. The company provides cosmetic, over-the-counter, and prescription products under the Obagi Medical, Obagi Clinical, and Obagi Professional brands. | In the after-hours, the company reported Q2 2024 financial results. | Highlights include: | $63.3 million of Net Revenue Q2 2024 | +25.7% net revenue Comparable Growth: | +30.9% Obagi Medical and +20.0% Milk Makeup vs Q2 2023 | Adjusted EBITDA of $6.3 million, up +64.5% vs Q2 2023 | The stock traded up over 20% in the pre-market in reaction to the positive financial results. | | The first target to the upside is prior resistance at $3.60. Above that, $4 and then the after-hours high at $4.62 come into play. | Below $3.60, targets to the downside are $3.40, $3.20, $3.09 and then a gap fill at $2.90. | | NRSN - Up over 14% in pre after reports it's in advanced talks with several multi-billion-dollar pharma companies to partner its lead drug | NeuroSense Therapeutics Ltd. (NRSN) is a clinical-stage biotechnology company that focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. | In the pre-market, it was reported that the company is currently in advanced discussions with several multi-billion-dollar pharmaceutical companies regarding a potential strategic partnership to develop and commercialize its lead drug candidate, PrimeC, for Amyotrophic Lateral Sclerosis (ALS). | These discussions, based on non-binding terms, indicate the potential for substantial financial benefits to NeuroSense, including upfront payments, milestone payments, and royalty payments as part of an agreement. | NeuroSense anticipates receiving terms from these discussions in the fourth quarter of 2024; however, there can be no assurance that terms will be finalized with any of the pharmaceutical companies, the timing, what the final terms would be, if any, or that a definitive agreement will be reached. | The stock traded up over 14% in the pre-market in reaction to the news. | | The $0.75 area found buyers this morning and will be an important level to watch. | Above it, targets to the upside are $0.77, $0.8350, $0.88 and then the after-hours high at $0.92. Beyond that, $1 and $1.15 come into play. | Below $0.75, targets to the downside are $0.72 and then $0.64. | | π₯Members Are Freaking Outπ₯ | Small Account Journey With Jason Bond! | 19 for 19 and +$5340 In JUST. ONE. WEEK. |  | Results not typical. Losses Happen. Don't expect to replicate. |
| Want The NEXT Small Account Journey Trades?! | Save 60% With The Code SAVE60! | Limited Time & Seats Remain |
|
| | BOX - Up over 8% in pre after reporting positive Q2 financial results | Box, Inc. (BOX) provides a cloud content management platform that enables organizations of various sizes to manage and share their content from anywhere on any device. | In the after-hours yesterday, the company reported Q2 2025 financial results. | Highlights include: | Revenue of $270 Million, up 3% Year-Over-Year, up 6% in Constant Currency | GAAP Operating Margin of 7.5% and Record Non-GAAP Operating Margin of 28.4% | GAAP Net Income Per Share of $0.10 and Record Non-GAAP Net Income Per Share of $0.44 | New $100 Million Expansion of Stock Repurchase Program | The stock traded up over 8% in the pre-market in reaction to the positive financial results. | | The first target for bulls is the after-hours high at $31.60. | Beyond that, $32, $33, $34 and $35 come into play. | Below $31.60, targets to the downside are $31, $30.50, $30, a gap fill at $28.82 and then $28. | | MARKET NEWS π° | | P.S. Make sure you text "RAGE" to (888) 404-5747 to get all of our latest HOT STOCK ideas! | | Questions or concerns about our products? Email Support@360wallstreet.io © Copyright 2022, RagingBull | | DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at https://ragingbull.com/disclaimer | FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. | RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. | RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers. | RagingBull.com, LLC shall be entitled to recover attorneys' fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys' fees, costs and disbursements in addition to any other relief to which it may be entitled. | *Sponsored Content: If you purchase anything through a link in this email other than RagingBull services, you should assume that we have an affiliate relationship with the company providing the product or service that you purchase, and that we will be paid in some way. We recommend that you do your own independent research before purchasing anything. We believe in the companies we form affiliate relationships with, but please don't spend any money on these products or services unless you believe they will help you achieve your goals. | WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. |
|
|
|
No comments:
Post a Comment